Associations of HNF1B rs4430796, CASC17 rs1859962, CASC8 rs1447295, and CCAT2 rs6983267 with prostate cancer risk: A systematic review and meta-analysis
Heading: Urology and andrology Article type: Review
Authors: Fomkin R.N., Popkov V.M., Fomkina O.A., Mezirov G.G., Osnovin O.V., Churakov A.A., Bucharskaya A.B.
Organization: Saratov State Medical University
Objective: to assess, in the allelic model, associations of HNF1B rs4430796, CASC17 rs1859962, CASC8 rs1447295, and CCAT2 rs6983267 with prostate cancer (PCa) risk. Review methodology. A systematic review and meta-analysis of genetic association studies was performed according to PRISMA 2020 (Preferred reporting items for systematic reviews and meta-analyses), PRISMA-S, and STREGA (STrengthening the REporting of Genetic Association studies). Searches were conducted in PubMed/MEDLINE, Google Scholar, eLIBRARY, CyberLeninka, journal websites, and reference lists; variant annotation databases were used only to verify rsID, locus, alleles, and frequencies. Twenty-nine publications were included in qualitative synthesis and 62 genotype strata in quantitative synthesis. Allelic odds ratio (OR) were recalculated de novo from 2×2 tables, and efect direction was harmonized by efect allele. Hardy – Weinberg equilibrium in controls was tested using Wigginton’s exact test. The primary random-efects model used the Paule – Mandel τ² estimator and Hartung – Knapp confdence intervals; DerSimonian – Laird was used for sensitivity analysis. Prediction intervals, Bonferroni correction, Egger’s test, an adapted Q-Genie-based domain assessment, and Venice/GRADE credibility assessment were applied. Conclusion. HNF1B rs4430796 showed the most stable inverse association: OR 0.81, 95% confdence interval (CI) 0.78–0.84, 95% prediction interval 0.78–0.84; p<0.001, I²=0.0%. CASC17 rs1859962 was associated with increased risk: OR 1.19, 95% CI 1.14–1.25, 95% prediction interval 1.14–1.25; p<0.001, I²=0.0%, although 40% of strata deviated from Hardy – Weinberg equilibrium. CASC8 rs1447295 showed a signifcant but highly heterogeneous association: OR 1.23, 95% CI 1.09–1.39, 95% prediction interval 0.73–2.06; p<0.001, I²=81.9%. CCAT2 rs6983267 showed no robust association: OR 1.03, 95% CI 0.92–1.16, 95% prediction interval 0.68–1.57; p=0.557, I²=76.6%; Egger’s test p=0.028. HNF1B rs4430796 represents the most reproducible signal; CASC17 rs1859962 and CASC8 rs1447295 require cautious interpretation; CCAT2 rs6983267 is not confrmed as a robust risk marker. Isolated clinical testing of these single nucleotide polymorphisms is not warranted; however, their laboratory detection is essential for population-based studies and polygenic risk scores, thereby justifying the development of a real-time PCR-based test system for their genotyping.
Bibliography:
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. DOI:10.3322/caac.21834
2. Kaprin AD, Starinskiy VV, Shakhzadova AO, eds. Malignant neoplasms in Russia in 2023: Morbidity and mortality. Moscow: P.A. Hertsen Moscow Oncology Research Institute, 2024; 276 p.
3. Cornford P, Tilki D, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. EAU Guidelines, 2026 ed. Arnhem: EAU Guidelines Ofce, 2026.
4. Conti DV, Darst BF, Moss LC, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identi-fes new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021;53(1):65-75. DOI:10.1038/s41588-020-00748-0
5. Schumacher FR, Al Olama AA, Berndt SI, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50(7):928-36. DOI:10.1038/s41588-018-0142-8
6. Al Olama AA, Kote-Jarai Z, Berndt SI, et al. A meta-anal-ysis of 87,040 individuals identifes 23 new susceptibility loci for prostate cancer. Nat Genet. 2014;46(10):1103-9. DOI:10.1038/ng.3094
7. Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007;39(8):977-83. DOI:10.1038/ng2062
8. Sun J, Zheng SL, Wiklund F, et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet. 2008;40(10):1153-5. DOI:10.1038/ng.214
9. Elliott KS, Zeggini E, McCarthy MI, et al. Evaluation of association of HNF1B variants with diverse cancers: Collaborative analysis of data from 19 genome-wide association studies. PLoS One. 2010;5(5):e10858. DOI:10.1371/journal.pone.0010858
10. Berndt SI, Wang Z, Yeager M, et al. Two susceptibility loci identifed for prostate cancer aggressiveness. Nat Commun. 2015;6:6889. DOI:10.1038/ncomms7889
11. Zhou CH, Wang JY, Cao S Y, et al. Association between single nucleotide polymorphisms on chromosome 17q and the risk of prostate cancer in a Chinese population. Chin J Cancer. 2011;30(10):721-30. DOI:10.5732/cjc.011.10070
12. Liu M, Suzuki M, Arai T, et al. A replication study examining three common single-nucleotide polymorphisms and the risk of prostate cancer in a Japanese population. Prostate. 2011;71(10):1023-32. DOI:10.1002/pros.21317
13. Zhang YR, Xu Y, Yang K, et al. Association of six susceptibility loci with prostate cancer in northern Chinese men. Asian Pac J Cancer Prev. 2012;13(12):6273-6. DOI:10.7314/ apjcp.2012.13.12.6273
14. Ren F, Zhang P, Ma Z, et al. Association of 17q24 rs1859962 gene polymorphism with prostate cancer risk: A systematic review and meta-analysis. Medicine (Baltimore). 2020;99(3):e18398. DOI:10.1097/MD.0000000000018398
15. Freedman ML, Haiman CA, Patterson N, et al. Admixture mapping identifes 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A. 2006;103(38):14068-73. DOI:10.1073/pnas.0605832103
16. Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38(6):652-8. DOI:10.1038/ ng1808
17. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifes a second risk locus at 8q24. Nat Genet. 2007;39(5):645-9. DOI:10.1038/ng2022
18. Haiman CA, Patterson N, Freedman ML, et al. Multiple regions within 8q24 independently afect risk for prostate cancer. Nat Genet. 2007;39(5):638-44. DOI:10.1038/ng2015
19. Schumacher FR, Feigelson HS, Cox DG, et al. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res. 2007;67(7):2951-6. DOI:10.1158/0008-5472.CAN-06-3591
20. Severi G, Hayes VM, Padilla EJ, et al. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: Results from an Australian population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2007;16(3):610-2. DOI:10.1158/1055-9965.EPI-06-0872
21. Suuriniemi M, Agalliu I, Schaid DJ, et al. Confrmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev. 2007;16(4):809-14. DOI:10.1158/1055-9965.EPI-06-1049
22. Zheng SL, Sun J, Wiklund F, et al. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst. 2007;99(20):1525-33. DOI:10.1093/jnci/djm169
23. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of fve genetic variants with prostate cancer. N Engl J Med. 2008;358(9):910-19. DOI:10.1056/NEJMoa075819
24. Cheng I, Plummer SJ, Jorgenson E, et al. 8q24 and prostate cancer: Association with advanced disease and meta-analysis. Eur J Hum Genet. 2008;16(4):496-505. DOI:10.1038/ sj.ejhg.5201959
25. Terada N, Tsuchiya N, Ma Z, et al. Association of genetic polymorphisms at 8q24 with prostate cancer risk
in a Japanese population. Prostate. 2008;68(15):1689-95. DOI:10.1002/pros.20831
26. Salinas CA, Kwon EM, FitzGerald LM, et al. Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(5):1203-13. DOI:10.1158/1055-9965.EPI-07-2811
27. Chen M, Huang S P, Huang LC, et al. Common variants at 8q24 are associated with prostate cancer risk in Taiwanese men. Prostate. 2010;70(5):502-7. DOI:10.1002/pros.21084
28. Liu M, Kurosaki T, Suzuki M, et al. Signifcance of common variants on human chromosome 8q24 in relation to the risk of prostate cancer in native Japanese men. BMC Genet. 2009;10:37. DOI:10.1186/1471-2156-10-37
29. Wokolorczyk D, Gliniewicz B, Sikorski A, et al. A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Res. 2008;68(23):9982-6. DOI:10.1158/0008-5472. CAN-08-1838
30. Benford ML, VanCleave TT, Lavender NA, et al. 8q24 sequence variants in relation to prostate cancer risk among men of African descent: A case-control study. BMC Cancer. 2010;10:334. DOI:10.1186/1471-2407-10-334
31. Liu M, Wang J, Xu Y, et al. Risk loci on chromosome 8q24 are associated with prostate cancer in northern Chinese men. J Urol. 2012;187(1):315-21. DOI:10.1016/j.juro.2011.09.011
32. Cheng I, Chen GK, Nakagawa H, et al. Evaluating genetic risk for prostate cancer among Japanese and Latinos. Cancer Epidemiol Biomarkers Prev. 2012;21(11):2048-58. DOI:10.1158/1055-9965.EPI-12-0598
33. Chan JY, Li H, Singh O, et al. 8q24 and 17q prostate cancer susceptibility loci in a multiethnic Asian cohort. Urol Oncol. 2013;31(8):1553-60. DOI:10.1016/j.urolonc.2012.02.009
34. Okobia MN, Zmuda JM, Ferrell RE, et al. Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry. Prostate. 2011;71(10):1054-63. DOI:10.1002/pros.21320
35. Papanikolopoulou A, Landt O, Reczko M, et al. The multi-cancer marker rs6983267, located at region 3 of chromosome 8q24, is associated with prostate cancer in Greek patients but does not contribute to the aggressiveness of the disease. Clin Chem Lab Med. 2012;50(2):379-85. DOI:10.1515/CCLM.2011.778
36. Penney KL, Salinas CA, Pomerantz M, et al. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009;15(9):3223-30. DOI:10.1158/1078-0432.CCR-08-2733
37. Brankovic AS, Brajuskovic GN, Nikolic ZZ, et al. Common variants at 8q24 are associated with prostate cancer risk in Serbian population. Pathol Oncol Res. 2013;19(3):559-69. DOI:10.1007/s12253-013-9617-1
38. Joung J Y, Park S, Yoon H, et al. Association of common variations of 8q24 with prostate cancer risk in Koreans and a review of the Asian population. BJU Int. 2012;110(6Pt B):E318-25. DOI:10.1111/j.1464-410X.2012.11211.x
39. San Francisco IF, Rojas PA, Torres-Estay V, et al. Association of RNASEL and 8q24 variants with the presence and aggressiveness of hereditary and sporadic prostate cancer in a Hispanic population. J Cell Mol Med. 2014;18(1):125-33. DOI:10.1111/jcmm.12171
40. Zheng SL, Sun J, Wiklund F, et al. Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men. Prostate. 2010;70(4):425-32. DOI:10.1002/pros.21076
41. Zeegers MP, Khan HS, Schouten LJ, et al. Genetic marker polymorphisms on chromosome 8q24 and prostate cancer in the Dutch population: DG8S737 may not be the causative variant. Eur J Hum Genet. 2011;19(1):118-20. DOI:10.1038/ejhg.2010.133
42. Li Q, Liu X, Hua RX, et al. Association of three 8q24 polymorphisms with prostate cancer susceptibility: evidence from a meta-analysis with 50,854 subjects. Sci Rep. 2015;5:12069. DOI:10.1038/srep12069
43. Tong Y, Yu T, Li S, et al. Cumulative evidence for relationships between 8q24 variants and prostate cancer. Front Physiol. 2018;9:915. DOI:10.3389/fphys.2018.00915
44. Polukonova NV, Fomkin RN, Pylaev TE, et al. Genetic polymorphisms of HNF1B, CASC17, CASC8 and CCAT2 genes associated with prostate cancer risk in urologic patients. Urolo-giia. 2025;(5):44-52. DOI:10.18565/urology.2025.5.44-52
45. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. DOI:10.1136/bmj.n71
46. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. DOI:10.1136/ bmj.n160
47. Rethlefsen ML, Kirtley S, Wafenschmidt S, et al. PRIS-MA-S: An extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev. 2021;10(1):39. DOI:10.1186/s13643-020-01542-z
48. Little J, Higgins JPT, Ioannidis JPA, et al. STrengthening the REporting of Genetic Association studies (STREGA): An extension of the STROBE statement. PLoS Med. 2009;6(2):e1000022. DOI:10.1371/journal.pmed.1000022
49. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy – Weinberg equilibrium. Am J Hum Genet. 2005;76(5):887-93. DOI:10.1086/429864
50. Sohani ZN, Meyre D, de Souza RJ, et al. Assessing the quality of published genetic association studies in meta-analy-ses: The quality of genetic studies (Q-Genie) tool. BMC Genet. 2015;16:50. DOI:10.1186/s12863-015-0211-2
| Attachment | Size |
|---|---|
| 02_maket_188-197.pdf | 2.2 MB |



